ClinicalTrials.Veeva

Menu

Proof-of-Concept Study of a Single Application of an Investigational Otic Suspension in Treatment of Acute Otitis Media With Tympanostomy Tubes

Alcon logo

Alcon

Status and phase

Terminated
Phase 2

Conditions

Acute Otitis Media

Treatments

Drug: AL-60371/AL-817 otic suspension
Drug: Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension

Study type

Interventional

Funder types

Industry

Identifiers

NCT01908803
C-13-026

Details and patient eligibility

About

The purpose of this study is to evaluate a single application of AL-60371/AL-817 Otic Suspension relative to ototopical CIPRODEX for sustained clinical cure, microbiological success, and time to cessation of otorrhea.

Full description

The results at the time of the interim analysis met the futility criteria and the study was subsequently stopped.

Enrollment

84 patients

Sex

All

Ages

6 months to 12 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Parent or guardian: Read and sign the informed consent. When required by the Institutional Review Board, child must agree to sign an approved assent form;
  • Presence of otorrhea (visible by parent or guardian) of 21 days or less in duration;
  • Presence of patent tympanostomy tubes;
  • Refrain from water immersion of the ears following surgery without the use of adequate ear protection during swimming, bathing, showering and other water-related activities;
  • Parent or guardian: Agree to comply with the requirements of the study, administer the study medication as directed, complete required study visits, and comply with the protocol;
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

  • NOT otorrhea-free for at least seven days following tympanostomy tube surgery;
  • Menarcheal females;
  • Previous otologic surgery, except tympanic membrane, within one year of study entry;
  • History of/or current acute or chronic non-tube otorrhea (through existing perforation of the eardrum);
  • Current acute otitis externa, malignant otitis externa, or other conditions which could interfere with evaluation of the study drug;
  • Diabetic (controlled or uncontrolled);
  • Use of prohibited medications;
  • Other protocol-defined exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

84 participants in 2 patient groups

AL-60371/AL-817
Experimental group
Description:
AL-60371/AL-817 otic suspension, 200 μL in affected ear(s) through tympanostomy tube on Day 1 (Visit 1)
Treatment:
Drug: AL-60371/AL-817 otic suspension
CIPRODEX
Active Comparator group
Description:
Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension, 4 drops in affected ear(s) twice daily through tympanostomy tube for 7 days
Treatment:
Drug: Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems